We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
Call your Senator and ask them to vote NO on the Graham-Cassidy bill, which would jeopardize access to healthcare for people with bleeding disorders.
The Partners in Bleeding Disorders Education Program recently launched a new online learning activity entitled, “Bacteremia: The Good, The Bad, and The Ugly.”
September 9, 2017 saw the passing of Harold R. Roberts, MD at the age of 87. Over the course of his more than 50-year career, the North Carolina native was a highly regarded physician, teacher, researcher, author and mentor in the field of hematology.
Researchers at the Boston Children’s Program in Cellular and Molecular Medicine and the Harvard Medical School recently made important discoveries relevant to the functioning of von Willebrand factor (VWF). The study, “Flow-induced Elongation of von Willebrand Factor Precedes Tension-Dependent Activation,” was published online, August 23, 2017, in the journal Nature Communications.
The U.S. Food and Drug Administration has accepted the Biologics License Application (BLA) and granted priority review for emicizumab, as a once-weekly treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors. Emicizumab, which is being co-developed by Chugai, Roche and Genentech, is unlike existing treatments in that it is administered subcutaneously via an injection just under the skin, instead of intravenously.